The Company’s Board of Directors resolved to convene the 2023 Annual General Shareholders’ Meeting

1.Date of the board of directors resolution:2023/03/13
2.General shareholders’ meeting date:2023/06/27
3.General shareholders’ meeting location: Masterlink Securities Education and Training Center(11F., No.97, Sec. 2, Dunhua S. Rd., Taipei City)
4.Shareholders meeting will be held by means of (physical shareholders meeting/ visual communication assisted shareholders meeting / visual communication shareholders meeting): physical shareholders meeting
5.Cause for convening the meeting I. Reported matters:
(1)2022 Business Report
(2)2022 Audit Committee’s Review Report
(3)Status of the Sound Operating Plan of the Company
(4)Amendments to the Company’s “Rules of Procedure for Board of Directors Meetings”
6.Cause for convening the meeting II.Acknowledged matters:
(1)2022 Annual Final Accounting Ledgers and Statements
(2)2022 Earnings Distribution Loss Off-setting
7.Cause for convening the meeting III.Matters for Discussion:
(1)Amendment of the Company’s “Articles of Incorporation”
(2)Amendment of the Company’s “Rules for Transaction with Related Parties, Specified Company and Group Enterprises”
(3)To coordinate with the plan of IPO of AP Biosciences, the affiliate company, the Company shall be able to disperse its shareholding of AP Biosciences in stages
(4)To coordinate with the plan of IPO of Obigen, the subsidiary, the Company shall be able to disperse its shareholding of Obigen in stages
(5)Ratification of the Company’s resolution to forfeit the subscription of AP Biosciences’ 2022 cash capital increase and distribute the rights to its shareholders
(6)Ratification of the Company’s resolution to forfeit part of subscription rights of Obigen’s 2022 cash capital increase and distribute the rights to its shareholders
8.Cause for convening the meeting IV.Election matters:
(1)By-election for one director of 7th Board of Directors
9.Cause for convening the meeting V.Other Proposals:
(1)Lifting of non-competition restrictions for the Company’s directors
10.Cause for convening the meeting VI.Extemporary Motions:None
11.Book closure starting date:2023/04/29
12.Book closure ending date:2023/06/27
13.Any other matters that need to be specified:
Pursuant to Article 172-1 of the Company Act, the Annual General Meeting will accept proposals by shareholders holding more than 1% of shares from 2023/4/17 to 2023/4/27. Shareholders shall submit the proposal with applicable contact information before 5:00 pm on 2023/4/27 for the Board of Directors to review and respond. (Please mark the letter “Proposal for Annual General Meeting“ and send it by priority mail). Overdue will not be accepted.
Proposal receiving office is the Financial Department of OBI Pharma Inc. (Address: 7th Floor, No. 369, Section 7, Zhongxiao East Road, Taipei City, Tel: 02-27866589, ext. 115/157). The shareholders will be able to exercise their voting rights electronically from 2023/5/28 to 2023/6/24. The electronic voting system is managed by Taiwan Depository and Clearing Corporation at